<DOC>
	<DOCNO>NCT02086188</DOCNO>
	<brief_summary>The purpose study determine treatment Mirabegron improve urinary urgency control beyond achieve pelvic floor exercise alone</brief_summary>
	<brief_title>Study Behavioral Modification Program Mirabegron Improve Urinary Urgency Multiple Sclerosis</brief_title>
	<detailed_description>A randomized 1:1 placebo control 10-week study mirabegron add-on therapy educational intervention behavioral modification include pelvic floor exercise ( BM-PFE ) cohort 40 Multiple Sclerosis ( MS ) subject overactive bladder ( OAB ) . Trial last approximately 12 week subject , include screening period treatment period . Active drug mirabegron 25mg daily optional up-titration 50mg daily approximately 5 week . Subjects randomize Baseline Visit base recording void diary keep 72 continuous hour screen period . Voiding diary 72 hour period utilized screening period , Phone Visit 1 Titration Phone Visit 2 Final Visit . In diary , subject record time micturition and/or urgency episode , urine volume void ( available ) , episode incontinence , severity urgency ( Overactive Bladder Symptom Composite Score , mean 72 hour total daily cumulative score . Primary outcome average daily OAB-SCS total score , Final Visit vs. Baseline . This account frequency , urgency incontinence component OAB .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Confirmed diagnosis Multiple Sclerosis ( MS ) ( subtype restriction ) Age ≥18 No change disease modify therapy 60 day . Patient willing able complete micturition diary Urinary urgency ( 8 entry bladder urgency score ≥2 ) 72hr void diary record screening period Micturition frequency ≥ 8 / day incontinence ≥ 2 episode 72 hour void diary record screening period At least 36 hour void activity record 72 hour void diary screening period Nonantimuscarinic medication likely influence bladder function may initiate screen study completion . They may continue dose change study . Discontinued use antimuscarinics least two week prior screen Able give inform consent Females breastfeeding , pregnant potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) Multiple Sclerosis exacerbation within 30 day screen Cognitive deficit would interfere subject 's ability give inform consent perform study test Screening blood pressure &gt; 165 systolic 100 diastolic History allergy Mirabegron Screening postvoid residual &gt; 200ml Evidence urinary tract infection screen Evidence chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy , previous current malignant disease pelvic organs Intravesical botulinum toxin treatment within previous six month screen . Presence InterStim device Use indwelling catheter selfcatheterization Concurrent use thioridazine ( Mellaril® MellarilS® , flecainide ( Tambocor® ) , propafenone ( Rythmol® ) digoxin ( Lanoxin® ) Concurrent use antimuscarinics : oxybutynin ( Ditropan® , Ditropan XL ® ) , tolterodine ( Detrol® , Detrol LA® ) , fesoterodine extendedrelease ( Toviaz® ) , solifenacin ( Vesicare® ) , trospium ( Sanctura® , Sanctura XR® ) , darifenacin extend release ( Enablex® ) Screening estimate glomerular filtration rate ( eGFR ) &lt; 60 , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2x upper limit normal Any serious and/or unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Incontinence</keyword>
	<keyword>Voiding</keyword>
	<keyword>Bladder Urgency</keyword>
	<keyword>Pelvic Floor Exercises</keyword>
</DOC>